echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Sumitomo Pharmaceutical's new target schizophrenia new drug application for clinical application

    Sumitomo Pharmaceutical's new target schizophrenia new drug application for clinical application

    • Last Update: 2021-05-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 25, the official website of CDE showed that the clinical application for SEP-363856 tablets of Sumitomo Pharmaceuticals has been accepted by the State Food and Drug Administration.


    SEP-363856 is a new type of trace amine related receptor 1 (TAAR1) and serotonin 1A (5-HT1A) receptor agonist.


    In April 2020, the results of a key clinical study of SEP-363856 in the treatment of schizophrenia code-named SEP361-201 were published in the New England Journal of Medicine.


    The results of the study showed that the total PANSS score of the patients in the SEP-363856 group decreased by 17.


    In terms of safety, 7 patients (5.


    SEP-363856 is currently undergoing a global Phase III clinical (DIAMOND) project to evaluate its efficacy against other types of schizophrenia.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.